Kezar Life Sciences Stock Price, News & Analysis

Kezar Life Sciences (KZR) announced the presentation of three posters at the American College of Rheumatology (ACR) Convergence 2022 from November 10-14 in Philadelphia, PA. The key presentation will feature full data from the Phase 2 MISSION study, where all 17 patients completed a 37-week trial of Zetomipzomib (KZR-616). Additional findings will be shared that are not included in the abstract. The presentations will cover topics like health-related quality of life in lupus nephritis patients and healthcare cost management.

Kezar Life Sciences, Inc. announced the granting of a nonqualified stock option to one employee for 18,000 shares at an exercise price of $10.10 per share. This grant aligns with the closing price on September 1, 2022. The stock option will vest over four years, starting with 25% after the first anniversary of employment, followed by monthly vesting. This award is part of the company's 2022 Inducement Plan, aimed at attracting talent in its pursuit of innovative treatments for immune-mediated and oncologic disorders.

Kezar Life Sciences (NASDAQ: KZR), a biotechnology firm focused on innovative treatments for immune-mediated and oncologic disorders, announced that its Co-founder and Chief Scientific Officer, Christopher Kirk, PhD, will present at three upcoming investor conferences in September 2022. The events include the Wells Fargo Healthcare Conference in Boston on September 8, H.C. Wainwright's Global Investment Conference in New York on September 13, and Morgan Stanley's Global Healthcare Conference in New York on September 14. Webcasts will be available on the company's website post-event.

Kezar Life Sciences (NASDAQ: KZR) announced positive topline results from the MISSION Phase 2 trial of zetomipzomib for lupus nephritis, showing that 64.7% of patients achieved a 50% reduction in proteinuria. The company appointed Nick Mordwinkin as Chief Business Officer, enhancing its leadership team. Financially, Kezar reported cash, cash equivalents, and marketable securities totaling $306.8 million as of June 30, 2022, up from $208.4 million at the end of 2021. However, the company incurred a net loss of $16.2 million for the quarter.

Kezar Life Sciences announced the grant of stock options to its newly appointed Chief Business Officer, Nick Mordwinkin, totaling 200,000 shares at an exercise price of $9.35, equal to the stock's closing price on August 1, 2022. An additional employee received 60,000 shares under similar conditions. The options will vest over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing key personnel. Kezar focuses on treatments for immune-mediated and oncologic disorders, advancing candidates like Zetomipzomib and KZR-261.

Kezar Life Sciences (NASDAQ: KZR) announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwinkin brings over a decade of experience in healthcare, previously at Gilead Sciences and Ultragenyx Pharmaceutical. His expertise will shape Kezar's business development strategy as the company advances its lead candidates, zetomipzomib and KZR-261. Additionally, Kezar reported an unaudited cash position of approximately $307 million as of June 30, 2022, positioning it well for future growth.

Kezar Life Sciences, a clinical-stage biotechnology company, announced that Dr. Noreen Roth Henig, Chief Medical Officer, will participate in a panel at the William Blair Biotech Focus Conference in New York on July 13, 2022, at 11:00 am ET. The panel will discuss developing therapies against novel targets in autoimmune diseases. Kezar is focused on breakthrough treatments for immune-mediated and oncologic disorders, with its lead asset, Zetomipzomib, currently in Phase 2 trials for lupus nephritis.

Kezar Life Sciences announced the grant of nonqualified stock options to three employees, covering a total of 24,500 shares at an exercise price of $9.29 per share, aligned with the stock's closing price on July 1, 2022. These options are part of the company’s 2022 Inducement Plan and will vest over four years, with 25% vesting after the first year. Kezar focuses on breakthrough treatments for immune-mediated and oncologic disorders, including a Phase 2 trial for Zetomipzomib in lupus nephritis and a Phase 1 trial for KZR-261 targeting solid tumors.

Kezar Life Sciences (NASDAQ: KZR) announced positive topline results from the MISSION Phase 2 clinical trial of zetomipzomib, a selective immunoproteasome inhibitor for lupus nephritis (LN). Out of 17 patients, 64.7% achieved a significant renal response, with 35.2% attaining complete renal response. The treatment demonstrated a favorable safety profile, reducing prednisone usage significantly. Improvements were also noted in extra-renal disease activity associated with systemic lupus erythematosus (SLE). A conference call to discuss these results is scheduled for today at 4:30 p.m. ET.